Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luminespib + Erlotinib in EGFR-Resistant Lung Adenocarcinoma
NCT01259089Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Apr 2011
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Luminespib in lung adenocarcinoma, sponsored by Northwestern University. Started Apr 2011; status: completed.
02
Drugs
Luminespib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01259089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01259089.